Home › Funds › Soleus Capital Management, L.P. › TGTX
Soleus Capital Management, L.P. position in TGTX
TG THERAPEUTICS INC · Health Care
Soleus Capital Management, L.P. reported holding 2,556,168 shares of TGTX (TG THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$142.6M, representing 5.07% of its reported portfolio and ranking #4 among its reported holdings. Soleus Capital Management, L.P. has disclosed TGTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s TGTX position evolved
Soleus Capital Management, L.P. first disclosed a stake in TGTX in Q3 2023 at 2,884,382 shares (US$24.1M). The position peaked in Q2 2026 at 2,927,895 shares, worth US$160.9M. Across 13 filings, Soleus Capital Management, L.P. increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,556,168 shares valued at US$142.6M — a reduction of -371,727 shares quarter over quarter.. Notable position changes include a 77% trim in Q4 2023 (shares fell 11% over the following quarter), a 387% increase in Q1 2024 (shares rose 17% over the following quarter), a 71% increase in Q3 2025 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.88M | $24.11M | New |
| Q4 2023 | 650.00K | $11.10M | Reduce |
| Q1 2024 | 3.17M | $48.19M | Add |
| Q2 2024 | 3.65M | $64.85M | Add |
| Q3 2024 | 2.53M | $59.28M | Reduce |
| Q4 2024 | 2.68M | $80.71M | Add |
| Q1 2025 | 2.85M | $112.25M | Add |
| Q2 2025 | 2.24M | $80.76M | Reduce |
| Q3 2025 | 3.84M | $138.89M | Add |
| Q4 2025 | 3.14M | $93.58M | Reduce |
| Q1 2026 | 4.03M | $133.85M | Add |
| Q2 2026 | 2.93M | $160.86M | Reduce |
| Q3 2026 | 2.56M | $142.58M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in TGTX — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$145.4M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$113.3M), Hood River Capital Management LLC (US$90.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- CONGRESS ASSET MANAGEMENT CO 2.61M sh · $145.39M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.03M sh · $113.26M · Q3 2026
- Hood River Capital Management LLC 1.62M sh · $90.11M · Q3 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Penn Capital Management Company, LLC 480.88K sh · $26.88M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held TGTX?
Soleus Capital Management, L.P. has disclosed TGTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in TGTX?
As of Q3 2026, Soleus Capital Management, L.P. holds 2.56M shares of TGTX (TG THERAPEUTICS INC), valued at $142.58M, representing 5.07% of its reported portfolio and ranking #4.
Has Soleus Capital Management, L.P. been buying or selling TGTX?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in TGTX. The position peaked in Q2 2026 at 2.93M shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include CONGRESS ASSET MANAGEMENT CO, FRONTIER CAPITAL MANAGEMENT CO LLC, Hood River Capital Management LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.